Revista: | Annals of hepatology |
Base de datos: | PERIÓDICA |
Número de sistema: | 000415678 |
ISSN: | 1665-2681 |
Autores: | Vafiadis, Irene1 Trilianos, Panagiotis1 Vlachogiannakos, Jiannis1 Karagiorga, Markisia2 Hatziliami, Antonia2 Voskaridou, Ersi3 Ladas, Spiros D1 |
Instituciones: | 1Athens University, Medical School, Goudi, Atenas. Grecia 2Ayia Sophia Children’s Hospital, Thalassemia Unit, Goudi, Atenas. Grecia 3Laiko General Hospital, Thalassemia Unit, Goudi, Atenas. Grecia |
Año: | 2013 |
Periodo: | Jul-Ago |
Volumen: | 12 |
Número: | 4 |
Paginación: | 364-370 |
País: | México |
Idioma: | Inglés |
Tipo de documento: | Artículo |
Enfoque: | Analítico, descriptivo |
Resumen en inglés | HCV infection and transfusional iron overload in Thalassemic patients may result in liver disease. HCV treatment in Thalassemia has raised safety concerns. Aim. Estimate effectiveness and tolerability of interferon-based therapy in HCV-infected Thalassemic patients. Material and methods. Over a 12-year period, consecutive patients with β Thalassemia major (TM) and chronic hepatitis C received treatment. Liver biopsy, HCV-RNA and genotyping were performed beforehand. Sustained virological response (SVR) was defined as negative HCV-RNA 6 months post-treatment. Forty eight patients (26 M-22 F, mean age 39.8) were enrolled. Twenty nine patients were treated with conventional interferon alpha (IFNa) for 48 weeks (group A). Nineteen patients (10 naïve-9 previously IFNa experienced) received pegylated interferon (PEGIFN) (group B). Results. HCV-1 was found in 44%, HCV-2 in 14%, HCV-3 in 23% and HCV-4 in 19%. Group A: ten patients (38.5%) achieved SVR, 2 (7.5%) relapsed and 17 (54%) were non responders. Group B: five (28%) achieved SVR, 8 (44%) relapsed and 6 (28%) never responded. High HCV-RNA levels, genotype 1 and advanced liver fibrosis were independently associated with no response. Four patients (3 treated with IFNα, 1 with PEG-IFN) had to discontinue treatment due to complications. Conclusions. The response rate of IFN monotherapy in multi-transfused, HCV-infected Thalassemic patients is not inferior to that in nonmulti-transfused patients. IFNa administration is well-tolerated and should be recommended as initial treatment schedule in this setting |
Disciplinas: | Medicina |
Palabras clave: | Farmacología, Gastroenterología, Hepatitis crónica, Hepatitis C, Anemia, Talasemia, Terapia antiviral, Interferón pegilado |
Keyword: | Medicine, Gastroenterology, Pharmacology, Chronic hepatitis, Hepatitis C, Anemia, Thalassemia, Antiviral therapy, Pegylated interferon |
Texto completo: | Texto completo (Ver PDF) |